

## Office of Vermont Health Access Pharmacy Benefits Management Program DUR Board Meeting Agenda

## November 10, 2009 6:30 – 9:00 p.m.

1.	Executive Session  Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreemed (as provided by 33 VSA § 1998(f)(2))	<b>6:30 - 7:00</b> ents
2.	Introductions and Approval of DUR Board Minutes (Public Comment Prior to Board Action)	7:00 - 7:05
3.	<b>OVHA Pharmacy Administration Updates</b>	7:05 - 7:15
4.	Medical Director Update	7:15 - 7:20
5.	Follow-up Items from Previous Meeting  Simponi® (golimumab) Prefilled Injection Vectical® (calcitriol) Topical Ointment	7:20 - 7:25
6.	Clinical Update: Drug Reviews (Public comment prior to Board action)	7:20 – 8:00
	Abbreviated New Drug Reviews  Exforge HCT® (amlodipine/valsartan/hydrochlorothiazide) Table	et
	Full New Drug Reviews  Nucynta® (tapentadol) Tablet Nuvigil® (armodafinil) Tablet Savella® (milnacipran) Tablet	
7.	Review of Newly-Developed/Revised Clinical Coverage Criteria (Public comment prior to Board action)  Growth Hormones Lipotropics: Miscellaneous/Combinations (Lovaza® and Zetia®) Migraine Medications (Triptans)	8:00 - 8:10
8.	Drug Classes – Annual Review (Public comment prior to Board action) Class review documents available on OVHA web site 11/10/09 @  Long Acting Narcotics	8:10 – 8:40 12 Noon

<ul><li>No RetroDUR this month</li><li>Future Topics?</li></ul>	
10. New Drug Product Plan Exclusions (Consent Agenda Topic) (Will now be a quarterly agenda topic)	8:50 - 8:50
<ul><li>11. Updated New-to-Market Drug Monitoring Log (Consent Agenda</li><li>Now on OVHA website</li></ul>	Topic) 8:50 - 8:50
<ul> <li>12. General Announcements</li> <li>Selected FDA Safety Alerts</li> <li>Byetta® – altered kidney function</li> <li>Rituxan® - PML</li> </ul>	8:50 - 8:55
13. Adjourn	9:00

8:40 - 8:50

9. RetroDUR